AU656775B2 - Novel taurine-based pharmaceutical composition for administration by inhalation - Google Patents
Novel taurine-based pharmaceutical composition for administration by inhalation Download PDFInfo
- Publication number
- AU656775B2 AU656775B2 AU16659/92A AU1665992A AU656775B2 AU 656775 B2 AU656775 B2 AU 656775B2 AU 16659/92 A AU16659/92 A AU 16659/92A AU 1665992 A AU1665992 A AU 1665992A AU 656775 B2 AU656775 B2 AU 656775B2
- Authority
- AU
- Australia
- Prior art keywords
- document
- date
- taurine
- documents
- international
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229960003080 taurine Drugs 0.000 title claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 239000000443 aerosol Substances 0.000 claims abstract description 17
- 208000006673 asthma Diseases 0.000 claims abstract description 17
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 3
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000004071 soot Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000422252 Cales Species 0.000 claims 1
- 101100113688 Clitocybe nebularis clt6 gene Proteins 0.000 claims 1
- 241000283014 Dama Species 0.000 claims 1
- 101150086776 FAM3C gene Proteins 0.000 claims 1
- 241001125929 Trisopterus luscus Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- JNSGIVNNHKGGRU-JYRVWZFOSA-N diethoxyphosphinothioyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound CCOP(=S)(OCC)OC(=O)C(=N/OC)\C1=CSC(N)=N1 JNSGIVNNHKGGRU-JYRVWZFOSA-N 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- OQCQSNQEGNRYKL-UHFFFAOYSA-N 2-aminoethanesulfinic acid Chemical compound NCCS(O)=O.NCCS(O)=O OQCQSNQEGNRYKL-UHFFFAOYSA-N 0.000 description 1
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- -1 taurine amides Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9103693A FR2674434B1 (fr) | 1991-03-27 | 1991-03-27 | Nouvelle composition pharmaceutique a base de taurine pour l'administration par inhalation. |
| FR9103693 | 1991-03-27 | ||
| PCT/FR1992/000282 WO1992017170A1 (fr) | 1991-03-27 | 1992-03-27 | Nouvelle composition pharmaceutique a base de taurine pour l'administration par inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1665992A AU1665992A (en) | 1992-11-02 |
| AU656775B2 true AU656775B2 (en) | 1995-02-16 |
Family
ID=9411170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU16659/92A Ceased AU656775B2 (en) | 1991-03-27 | 1992-03-27 | Novel taurine-based pharmaceutical composition for administration by inhalation |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2696080B1 (fr) * | 1992-09-30 | 1994-12-23 | Jesus Covarrubias | Filtre à cigarette pour l'administration de taurine par inhalation. |
| KR100396362B1 (ko) * | 1999-07-02 | 2003-09-02 | 가부시키가이샤 닛뽕 가가꾸 고오교쇼 | 아미노에탄술폰산 함유 제제 |
| KR100368011B1 (ko) * | 2000-03-23 | 2003-01-14 | 조금호 | 타우린을 함유하는 경장유동액 |
| FR2833839A1 (fr) * | 2001-12-21 | 2003-06-27 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
| FR2833840B1 (fr) * | 2001-12-21 | 2010-06-18 | Rytek | Methodes et compositions pour le traitement de pathologies respiratoires |
| FR2879100B1 (fr) | 2004-12-09 | 2007-07-06 | Lionel Bueno | Compositions pour le traitement des pathologies oculaires de surface et de la retine |
| DE102007040615A1 (de) * | 2007-08-27 | 2009-03-05 | Bitop Ag | Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen |
| DE102008039231A1 (de) | 2008-08-22 | 2010-02-25 | Bitop Ag | Verwendung von Glucosylglycerol |
| GB201305813D0 (en) * | 2013-03-28 | 2013-05-15 | Vectura Ltd | Compositions and methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1226897B (it) * | 1987-09-18 | 1991-02-21 | Richerche Di Schiena Snc Del D | Derivato di taurina, sua preparazione e composizioni farmaceutiche relative |
| JPH0368549A (ja) * | 1989-08-07 | 1991-03-25 | Yamanouchi Pharmaceut Co Ltd | タウリン誘導体及びこれを有効成分とするロイコトリエン拮抗剤 |
-
1991
- 1991-03-27 FR FR9103693A patent/FR2674434B1/fr not_active Expired - Fee Related
-
1992
- 1992-03-27 DE DE69213874T patent/DE69213874T2/de not_active Expired - Fee Related
- 1992-03-27 CA CA002083825A patent/CA2083825A1/fr not_active Abandoned
- 1992-03-27 KR KR1019920702994A patent/KR100196060B1/ko not_active Expired - Fee Related
- 1992-03-27 BR BR9204815A patent/BR9204815A/pt not_active Application Discontinuation
- 1992-03-27 EP EP92909536A patent/EP0533896B1/fr not_active Expired - Lifetime
- 1992-03-27 ES ES92909536T patent/ES2093829T3/es not_active Expired - Lifetime
- 1992-03-27 JP JP4508593A patent/JPH06501954A/ja active Pending
- 1992-03-27 AT AT92909536T patent/ATE142874T1/de active
- 1992-03-27 WO PCT/FR1992/000282 patent/WO1992017170A1/fr active IP Right Grant
- 1992-03-27 DK DK92909536.2T patent/DK0533896T3/da active
- 1992-03-27 AU AU16659/92A patent/AU656775B2/en not_active Ceased
- 1992-11-26 NO NO924578A patent/NO301521B1/no unknown
-
1996
- 1996-12-18 GR GR960403529T patent/GR3022083T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0533896T3 (enrdf_load_html_response) | 1997-02-17 |
| DE69213874T2 (de) | 1997-04-03 |
| ATE142874T1 (de) | 1996-10-15 |
| EP0533896B1 (fr) | 1996-09-18 |
| ES2093829T3 (es) | 1997-01-01 |
| FR2674434A1 (fr) | 1992-10-02 |
| KR930700088A (ko) | 1993-03-13 |
| KR100196060B1 (ko) | 1999-06-15 |
| GR3022083T3 (en) | 1997-03-31 |
| DE69213874D1 (de) | 1996-10-24 |
| BR9204815A (pt) | 1993-07-27 |
| NO924578D0 (no) | 1992-11-26 |
| NO301521B1 (no) | 1997-11-10 |
| NO924578L (no) | 1992-11-26 |
| JPH06501954A (ja) | 1994-03-03 |
| EP0533896A1 (fr) | 1993-03-31 |
| FR2674434B1 (fr) | 1993-06-18 |
| WO1992017170A1 (fr) | 1992-10-15 |
| CA2083825A1 (fr) | 1992-09-28 |
| AU1665992A (en) | 1992-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU656775B2 (en) | Novel taurine-based pharmaceutical composition for administration by inhalation | |
| Cao et al. | The free radical scavenger, α-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils | |
| DE69526517D1 (de) | Treibgasmischung für eine aerosolzubereitung | |
| BR0317595A (pt) | Método e aparelho para produzir partìculas, método para produzir uma mistura de pó seco e composição farmacêutica | |
| Inoue et al. | Determination of catechol and quinol in the urine of workers exposed to benzene. | |
| PT95237B (pt) | Processo de preparacao de 4-hidroxi-tetrahidropirano-2-onas e dos respectivos derivados de acidos dihidroxi-carboxilicos, sais e esteres, bem como de composicoes farmaceuticas que os contem e de compostos intermediarios | |
| JPH092944A (ja) | 眼用医薬組成物及びその投与方法 | |
| Kulling et al. | Fatal systemic poisoning after skin exposure to monochloroacetic acid | |
| ITMI981743A1 (it) | Sali nitratti di farmaci | |
| Alagarsamy et al. | Dopamine neurotoxicity in cortical neurons | |
| Browning et al. | Clinical Toxicology of Ethylene Glycol Monoal Ethers | |
| MX2007001822A (es) | Uso de xenon como neuroprotector en un individuo neonatal. | |
| CN112056317B (zh) | 汉防己碱脂质体、其制法、及含有其的医用口罩 | |
| Kimmel et al. | Influence of acid aerosol droplet size on structural changes in the rat lung caused by acute exposure to sulfuric acid and ozone | |
| US20210380518A1 (en) | Compounds and methods of using compounds for treatment of respiratory diseases | |
| Wong | B3 Carbon Dioxide | |
| BR9911703A (pt) | Inalação de ativos de aerosol | |
| Klonne et al. | Acute toxicity and primary irritation of para-tertiary butylphenol | |
| CA2353529C (en) | Method for reducing free-radical induced injury | |
| AU697290B2 (en) | Pharmaceuticals | |
| US6894079B1 (en) | Method for reducing free-radical induced injury | |
| Lee | Metabolism and pharmacology of fluorine-containing compounds | |
| Bowman et al. | Amiodarone-Induced Pulmonary Toxicity (AIPT) in F344 Rats | |
| Castranova et al. | Cytotoxicity of Abrasive Blasting Substitutes | |
| Hardin | Occupational exposure to xylene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |